branebrutinib + rosuvastatin

This is a combination of two small molecule drugs: **branebrutinib**, an investigational irreversible inhibitor of Bruton's tyrosine kinase (BTK), and **rosuvastatin**, an approved HMG-CoA reductase inhibitor (statin) primarily used to lower cholesterol. The combination has been studied in healthy volunteers to assess potential drug-drug interactions, particularly regarding the effect of branebrutinib on the pharmacokinetics of rosuvastatin, which is a substrate for the breast cancer resistance protein (BCRP) transporter. There is no evidence that this combination has a specific clinical indication as a marketed or investigational fixed-dose product, and no approval as a combination drug[2][3][5][6][7].